3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
440
Lung Neoplasms
170
Neoplasms
31
Adenocarcinoma of Lung
27
Neoplasm Metastasis
23
Breast Neoplasms
23
Prostatic Neoplasms
19
Squamous Cell Carcinoma of Head and Neck
17
Small Cell Lung Carcinoma
17
Colorectal Neoplasms
13
Melanoma
12
Stomach Neoplasms
11
Adenocarcinoma, Bronchiolo-Alveolar
11
Pancreatic Neoplasms
10
Ovarian Neoplasms
10
Carcinoma, Renal Cell
10
Head and Neck Neoplasms
9
Urinary Bladder Neoplasms
8
Recurrence
8
Esthesioneuroblastoma, Olfactory
8
Carcinoma, Squamous Cell
8
Salivary Gland Neoplasms
7
Esophageal Neoplasms
7
NSCLC
6
Carcinoma
6
Advanced Non-Small Cell Lung Cancer
6
Sarcoma
5
Pleural Effusion, Malignant
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Carcinoma, Transitional Cell
5
Interventions
Carboplatin
15
Pemetrexed
7
Paclitaxel
7
pembrolizumab
4
durvalumab
4
osimertinib
3
entinostat
3
Gemcitabine
3
Erlotinib Hydrochloride
3
Cisplatin
3
selpercatinib
2
pralsetinib
2
efatutazone
2
atezolizumab
2
Radiosurgery
2
taletrectinib
1
sotorasib
1
repotrectinib
1
patritumab
1
necitumumab
1
napabucasin
1
ficlatuzumab
1
exemestane
1
cobimetinib
1
ceralasertib
1
cemiplimab
1
camrelizumab
1
alectinib
1
aflutinib
1
Vinorelbine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Respiratory Tract Neoplasms
×
Docetaxel
×
Thoracic
×
Clear all
NCT03402048
2020-11-04
EPIC
University of Turin, Italy
Phase 3
Unknown
567 enrolled